The global hemato oncology testing market size was valued at 2.5 billion in 2021, growing at a CAGR of 14.8% during the forecast period 2022 to 2028. In terms of incidence rate and cause of mortality in cancer patients, haematological malignancies are among the top 10 malignant illnesses. They account for approximately 9% of all cancer cases diagnosed each year. Haemato oncologists rely on geneticists for not only diagnostic testing, but also for critical understanding of cancer genetics that helps them assess their patients' prognosis, choose the best anticancer treatment, and track therapeutic efficacy.

View detailed report description here https://precisionbusinessinsights.com/market-reports/hemato-oncology-testing-market/           

The market is predicted to expand due to the expansion of sequencing techniques such as NGS due to the rising cost of development and the sequencing of the Human Genome Project in the field of genomics. Major players in the personalised medicine sector are frequently participating in numerous precision medicine investment programmes. Companies also offer a variety of molecular decision support systems that use genetic and clinical data to close gaps in precision medicine practise. Furthermore, a recent research study performed by Bloodwise, a blood cancer research charity team, in 2018 revealed promising results for the research study, which is expected to make personalised medication more accessible for the treatment of Acute Myeloid Leukemia (AML) in the coming years. One of the primary factors driving the growth of the hemato oncology testing market is the increased availability of advanced molecular techniques for the diagnosis of hemato oncology. The development of improved molecular methods has been essential in resolving concerns about blood cancer prognosis, treatment, as well as diagnosis.

The global hemato oncology testing market segmentation:
1) By Product & Service: Services and Assay kit.
2) By Cancer Type: Leukemia, Acute myeloid leukemia, Acute lymphocytic leukemia, Lymphoma, Non-Hodgkin lymphoma, Hodgkin lymphoma, and others.
3) By Technology: PCR, IHC, NGS, Cytogenetics, and others.
4) By End User: Clinical laboratories, Hospitals, Academic & Research institute, and others.

During the projected timeline, North America is expected to dominate the worldwide hemato oncology testing market. During the projected timeframe, the hemato oncology testing market in the area is likely to be driven by new product launches and the presence of significant market players with a strong focus on research and development. During the forecast period, the Asia Pacific hemato oncology testing market is expected to grow at a quick rate. Government attempts to improve healthcare facilities are also expected to boost the market.

Request sample report at  https://precisionbusinessinsights.com/request-sample?product_id=42389                                                                                                      

Some of the major key players in the Hemato Oncology Testing Market are Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., QIAGEN N.V., Bio-Rad Laboratories Inc.

Precision Business Insights: 
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:
Mr. Satya
Precision Business Insights | Toll-Free: +1 866 598 1553
Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747